S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Published on March 20, 2023
As filed with the Securities and Exchange Commission on March 20, 2023
Registration No. 333 -
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
GRAPHITE BIO, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
|
84-4867570 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
201 Haskins Way, Suite 210 |
||
South San Francisco, CA 94080 |
||
(650) 484-0886 |
||
(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices) |
||
Graphite Bio, Inc. 2021 Stock Option and Incentive Plan |
||
Graphite Bio, Inc. 2021 Employee Stock Purchase Plan |
||
|
||
Josh Lehrer, M.D. |
||
President and Chief Executive Officer |
||
201 Haskins Way, Suite 210 |
||
South San Francisco, CA 94080 |
||
(650) 484-0886 |
||
(Name, address, including zip code, and telephone number, including area code, of agent for service) |
|
Copies to: |
|
|
|
|
Mitchell S. Bloom |
|
Josh Lehrer, M.D. |
Maggie Wong |
President and Chief Executive Officer |
|
Shoaib Ghias |
201 Haskins Way, Suite 210 |
|
Goodwin Procter LLP |
South San Francisco, CA 94080 |
|
Three Embarcadero Center, Floor 28 |
(650) 484-0886 |
|
San Francisco, CA 94111 |
|
|
(415) 733-6000 |
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers 2,911,088 additional shares of Common Stock under the Graphite Bio, Inc. 2021 Stock Option and Incentive Plan (the “2021 Plan”) and 564,000 additional shares of Common Stock under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The number of shares of Common Stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1, beginning January 1, 2022, by an amount equal to the lesser of: (i) 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (ii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in the 2021 Plan). Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the 2021 Plan increased by 2,911,088. The number of shares of Common Stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on each January 1, beginning January 1, 2022, by an amount equal to the least of: (i) 564,000 shares of Common Stock, (ii) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in the 2021 ESPP). Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the 2021 ESPP increased by 564,000. The additional shares are of the same class as other securities relating to the 2021 Plan and the 2021 ESPP for which the Registrant’s registration statements filed on Form S-8 filed with the Securities and Exchange Commission on June 28, 2021 (File No. 333-257486) (the “2021 Registration Statement”) and on March 21, 2022 (File No. 333-263747) (the “2022 Registration Statement”) are effective, and the contents of the 2021 Registration Statement and 2022 Registration Statement, as amended, or as modified or superseded pursuant to Rule 412 under the Securities Act of 1933, as amended (the "Securities Act"), are incorporated by reference into this Registration Statement.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8 Exhibits
EXHIBIT INDEX
Exhibit Number |
Description |
4.1 |
|
4.2 |
|
4.3 |
|
4.4 |
|
5.1* |
|
23.1* |
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm. |
23.2* |
|
24.1* |
Power of Attorney (included on signature page to this registration statement). |
99.1 |
|
99.2 |
|
107* |
|
* |
Filed herewith |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this 20th day of March, 2023.
|
|
GRAPHITE BIO, INC. |
|
|
|
|
By: |
/s/ Josh Lehrer |
|
|
Name: Josh Lehrer, M.D. |
|
|
Title: President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Josh Lehrer and Alethia Young as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their capacities and on the date indicated.
NAME |
TITLE |
DATE |
|
|
|
/s/ Josh Lehrer |
President, Director and Chief Executive Officer |
March 20, 2023 |
Josh Lehrer, M.D. |
(Principal Executive Officer) |
|
|
|
|
/s/ Alethia Young |
Chief Financial Officer |
March 20, 2023 |
Alethia Young |
(Principal Financial and Accounting Officer) |
|
|
|
|
/s/ Perry Karsen |
Chairman of the Board and Director |
March 20, 2023 |
Perry Karsen |
|
|
|
|
|
/s/ Abraham Bassan |
Director |
March 20, 2023 |
Abraham Bassan |
|
|
|
|
|
/s/ Jerel Davis |
Director |
March 20, 2023 |
Jerel Davis, Ph. D. |
|
|
|
|
|
/s/ Kristen M. Hege |
Director |
March 20, 2023 |
Kristen M. Hege, M.D. |
|
|
|
|
|
/s/ Joseph Jimenez |
Director |
March 20, 2023 |
Joseph Jimenez |
|
|
|
|
|
/s/ Matthew Porteus |
Director |
March 20, 2023 |
Matthew Porteus, M.D., Ph.D. |
|
|
|
|
|
/s/ Carlo Rizzuto |
Director |
March 20, 2023 |
Carlo Rizzuto, Ph.D. |
|
|
|
|
|
/s/ Smital Shah |
Director |
March 20, 2023 |
Smital Shah |
|
|
|
|
|
/s/ Jo Viney |
Director |
March 20, 2023 |
Jo Viney, Ph.D. |
|
|